
Founder & CEO of @SocialStation
Allentown, PA
Joined April 2009
- Tweets3.5K
- Following707
- Followers1.2K
- Likes1K
Alex Kalogeropoulos retweeted
An open offer to Tesla: We fully support putting Cybercab first, and we’d be glad to take the Cybertruck line off your hands.
We’d fund it with a consortium of investors and run it at no cost to Tesla’s floor space, headcount, or focus. All of that goes to Cybercab. Cybercab gets first call on battery cells too. We’ll wait our turn.
Tesla gains incremental profit: a license fee, plus FSD and Robotaxi network revenues on every vehicle built.
We’d build the Cybertruck, a three-row CyberSUV, and an unmanned CyberCargo hauler. More autonomous miles, across every surface of this planet and beyond.
Worth a conversation?
Alex Kalogeropoulos retweeted
In January 2025 my mom’s lung cancer spread to her brain. The drug with the best chance of helping her was approved in China but not here.
A doctor told me, almost as an aside, that if she were Chinese she could buy it at a pharmacy.
So I flew to Shanghai and came home with 26 boxes in my luggage. That was 19 months ago. My mom is still here, still working, and in her words has had an amazing three years.
The drug was approved in China in 2023. The FDA approved it in July 2025. It still is not for sale here. I know of at least 30 Americans who have made the same trip.
I have been scared to tell this story because I worried it could cost my mom access to the medicine keeping her alive. But the problem matters more than my silence. These drugs need to be developed and available here, and that means FDA reform.
Art Allen at KFF Health News told our story this week. It also ran in The Washington Post.
kffhealthnews.org/health-ind…
Alex Kalogeropoulos retweeted
Dr. Kesari is THA MAN...what a great paper showing spinal tap followed by sophisticated DNA + RNA sequencing provides a high-resolution molecular picture of brain/CNS cancer—helping diagnose it, identify drug targets, and potentially monitor whether treatment is working.
journalofliquidbiopsy.com/ar…
Alex Kalogeropoulos retweeted
I've attempted to map everything in oncology in a public website and open source repo for all.
The site is trying to get all cancers, products, technologies, bottlenecks, people, startup opportunities with 1000+ ideas for upgrading the field.
If you have a loved one with cancer and you are technical or can engineer, go take a look, file improvement requests or bugs or help with the open repo and make this the best open and free info resource for individuals, researchers and educational use.
This should save people time, aid AI oncology projects and generate positive action. If you are not technical just complain in this thread about broken or annoying or things you want and I'll fix them live.
Some of the interesting pages:
Treatments: onco.cc/drugs
A gallery of the molecules being used onco.cc/molecules/
And targets: onco.cc/targets/
The technologies in oncology: onco.cc/technologies/
1100 ideas for helping oncology: onco.cc/ideas/
Bottlenecks on oncology: onco.cc/bottlenecks/
Open questions (LETS GO RESEARCH PEOPLE) onco.cc/open-questions/
Startup requests (LETS GO STARTUP PEOPLE) onco.cc/startup-requests/
Mechanics of cancer: onco.cc/mechanics
Battlefronts: onco.cc/fronts/
Isotope supply: onco.cc/isotopes
Key papers: onco.cc/key-papers
Pipeline funnels: onco.cc/pipeline
Cancer by type: onco.cc/cancers/
Institutional rankings: onco.cc/institutions/
The startups: onco.cc/startups/
Heros and heroines : onco.cc/heroes/
Key medical people: onco.cc/people/
Here is the project roadmap: onco.cc/roadmap/
Models and data sets: onco.cc/models/
There are other views as well, take a browse.
Try making a PR if you have an upgrade to this on the repo here: github.com/judegomila/OnCo
If you are biologically/medically minded and something is wrong, file a bug as well or say on the thread and we will get it fixed live.
If this is a useful project star the repo and help get it calibrated.
I've tried to add some other languages but I cannot speak them so tell me if that doesnt work well.
I believe we will crack oncology and having total information dominance is key to the problem.
Let the feedback flow!
Alex Kalogeropoulos retweeted
Starting a new thing at UNC with @BenjaminGVincen to figure out which tumor-specific pMHCs are actually on tumor cells & which vaccine platforms are more immunogenic.
Lots of long-read WGS/scRNA, targeted mass spec, tumor-specific TCRs coming your way in the near future
Alex Kalogeropoulos retweeted
If AI will cure all diseases within a decade, slowing it down is mass murder.
Alex Kalogeropoulos retweeted
1) AI will not eradicate humanity. Humans survived an ice age, the Black Death, two world wars, and (so far) the advent of nuclear weapons. Anyone who is loudly warning of AI-caused human extinction should not be taken seriously.
2) If you worked in a company where you anticipated a 10% chance that your product would kill ten people, let alone all people, the correct response would be horror, ceasing all operations, and likely contacting the police or other criminal authorities. I am obviously no Coxon booster but at least his behavior is in line with his stated beliefs. Any current AI company employees saying "yes, me too, the thing we are building and about to IPO may kill all humans" should, again, not be taken seriously. Their actions betray their actual beliefs.
3) Antitrust law does not prevent AI companies from coordinating to make sure AI does not hurt people. It does not prevent companies working together to make sure it doesn't hack people; the DOJ and FTC made this clear a decade ago when they issued a policy statement saying that the agencies "do not believe that antitrust is – or should be – a roadblock to legitimate cybersecurity information sharing." The same principles apply here. See: justice.gov/archives/opa/pr/…
4) Antitrust law does absolutely prevent AI companies from organizing to prevent the entry of cheaper, upstart rivals because the bigger companies are burning cash and failing to achieve sufficient profitability. The panic of individual employees may be sincere if misguided, but the moves by their CEOs to achieve some kind of broad "antitrust waiver" or "exemption" should be meet with deep skepticism in light of the economics of the industry and the threat they face from open models.
Alex Kalogeropoulos retweeted
The big labs have achieved RSI and want to ban common people from owning and controlling intelligence, crystallize their cartel, and cement their current power forever
Alex Kalogeropoulos retweeted
Dear cancer patients in 2030,
Sorry, but you are gonna die, we decided to pace frontier AI so the cure will only be available after 2035.
Sincerely,
AI labs in 2026
Alex Kalogeropoulos retweeted
We are on the cusp of a wave of new therapies for some of the worst diseases. But the world won’t benefit unless the US fixes its drug regulatory system. My new essay for @nytimes, on how slow clinical trials are now the biggest obstacle to curing cancer.
nytimes.com/2026/09/04/opini…
- I interviewed dozens of researchers, especially oncologists at leading U.S. centers. A striking consensus emerged: science is no longer the main bottleneck to new cancer drugs. It is our ability to test discoveries in patients through clinical trials.
- The cost of starting a Phase 1 trial in America has roughly doubled over the past decade. As a result, companies increasingly take early trials abroad: Australia’s Phase 1 trial volume has nearly doubled in a decade, driven mainly by U.S. companies.
- Unfortunately, the underlying incentives are badly asymmetric: Institutions can be blamed for harms caused by moving too fast, but almost no one is blamed when patients deteriorate during avoidable delays. One doctor called the emerging system “ritualized safety over actual risk assessment.” Or as, @DavidHongMD put it: "We often forget that the biggest risk is the cancer itself."
- This problem is becoming more urgent because medicine itself is changing. Sequencing, biological engineering and A.I. make increasingly personalized therapies possible. But our regulatory system was mostly built for standardized drugs tested in large populations.
- @sytse, the co-founder of GitLab, shows what personalized medicine can achieve: after relapsed osteosarcoma and being told there were no options left, he pursued a highly individualized approach and has now been cancer-free for a year. But doing so required extraordinary resources and regulatory expertise.
- Pierce Ogden’s father was less lucky. After molecular analysis identified a drug that might target his glioblastoma, the manufacturer agreed to provide it. But administrative barriers delayed access until it was too late. “My dad was ready to try anything,” Pierce told me. “But the system is paternalistic.”
- The A.I. revolution is making this bottleneck more important, not less. A.I. relies on relevant data. Information from early-stage trials could compound with A.I. tools to achieve truly revolutionary medicines. Without the data, this is far less likely to happen.
- Another important shift is that innovation increasingly comes from academic labs and small biotech companies rather than Big Pharma. These small companies find it far harder to unable to absorb delays and regulatory barriers.
- Apart from cancer, China is the biggest winner from America's outdated medical regulations. China has a much faster trial system, with testing often starting a full year earlier. This allows Chinese pharmaceutical companies to experiment and improve medicines while American companies play with mice. Today, half of all drugs licensed by major pharmaceutical companies originate there, up from less than 5 percent only a decade ago.
- But we don't need to copy China. The best model is Australia: lots of on-site scientific and ethics reviews, and requirements that are proportionate to small, early-stage trials. Phase 1 studies there begin roughly 6–12 months faster, without any notable increases in adverse safety events.
- Operation TrialBlazer, a 2026 HHS initiative is a good start in this direction, but we need legislative action by Congress to truly make Phase I trials faster and more efficient!
I want to thank everyone who helped me with this article: everyone I interviewed and the amazing editors at the Times. This is the result of a months long journey of extensive interviews and research.
Special thanks go to those who came on the record. One of the features of the system is an atmosphere of fear, where practitioners are afraid to publicly come out and explain these issues. So anyone who does is a hero in my book!
.@theNOBSdentistyou need to figure out how to make a
@nobsroutines compatible tablet for this! Supposedly you need to use their special toothpaste that is anti-foaming for the camera to work. I want to use this, but don't want to give up my NOBS! @Dyson
xitter.gq/SMB_Attorney/status/20…
The fastest $500 I’ve ever spent.
I went deep on this thing and was blown away. Here’s how it was developed and how it works:
Dyson spent 6 years, 661 engineers and 38 patents on the CameraJet.
The problem: most people miss the gaps between teeth, where plaque forms. Flossing is a separate step few do consistently.
The solution: a 100,000-pixel camera in the brush head captures 28 images per second.
An on-device AI system trained on 470,000 dental images identifies those gaps.
Within 100 milliseconds it fires a cone-shaped jet of mouthrinse into the gap.
That has to happen while the head vibrates at 58,000 movements a minute, in a dark, wet mouth.
Dyson also developed a synthetic plaque with the National University of Singapore to test the jet without running a new clinical trial after every change, and a low-foam toothpaste so the camera can see.
You brush as normal. The device handles the interdental cleaning at the same time.
Dyson’s published figures: up to 69% more plaque removed than market-leading premium electric toothbrushes in hard-to-reach areas (lab test).
In a 4-week clinical study versus a manual toothbrush, gum bleeding fell 65% vs 37%, and 74% of CameraJet users reached “healthy gums” versus 6% in the manual group.
$499 but you can’t put a price on health!
6
638
Anddddd looks like a great opportunity to buy $SPCX - going down after hours with the Starship scrub.
2
451
Got access to Fable 5 @claudeai - trying to use it for synthesis of my wife's medical data (something I was able to do just fine in Opus 4.8) and it won't - super frustrating.
Unfortunately useless for the main reason I would want to utilize it for.
.@spencerpratt heard you on @joerogan. Can confirm what you said about sitting on hold for 911. I’m from Pennsylvania out in LA for my wife’s cancer care. She passed out & I called 911. Never saw this before when calling 911 in PA. Didn’t know this was a thing. It was unsettling.
1
250
Alex Kalogeropoulos retweeted
People Deserve to Choose The Path That Makes Sense to Them – Lori Mills to Marty Makary
@LoriMills4CA42 @MartyMakary
oncodaily.com/voices/lori-mi…
#OncoDaily #Oncology #Cancer #Health #Medicine #MedX #MedTwitter
Alex Kalogeropoulos retweeted
Joe Rogan just posted about getting plasmapheresis.
His description of it - "Changing the oil in your body" is exactly how I describe it.
I'm an Associate Medical Director at Global Apheresis in Mill Valley, CA. We've performed thousands of these procedures. Our founder Dr. Kiprov helped establish this field in the 1980s and first hypothesized that it could be used for aging over a decade ago.
A few things people should know now that this is blowing up:
It's called therapeutic plasma exchange (TPE). It removes your plasma, which accumulates inflammatory proteins, autoantibodies, and aging-related molecules, and replaces it with fresh albumin.
The science is real. A 2022 clinical study showed TPE reduces biological age by 1 to 3 years. A 2025 Buck Institute study using 35 epigenetic clocks confirmed it.
A 322-patient randomized controlled trial showed it slowed Alzheimer's decline by 52 to 71% and a 2025 study with real-world patients in Argentina replicated those findings.
The "biologics alongside the plasma replacement" Rogan mentioned? That's likely IVIG, intravenous immunoglobulin. We do that too. The research shows the combination produces the strongest effect.
This is a field that may be having its moment, and rightfully so.
Alex Kalogeropoulos retweeted
$IBRX Cancer breakthrough:
Jim Johnson, a veteran of radiation and chemotherapy, says he’s #cancerfree after going through Dr. Patrick Soon-Shiong’s clinic.
Just watch yourself the clip from the Chris Cuomo show with @DrPatrick that just aired last night at NewsNation.
Alex Kalogeropoulos retweeted
Thank you @ChrisCuomo for keeping the spotlight on this critical fight against cancer, which has devastated so many lives.
My husband was diagnosed with glioblastoma and given just 12 months to live. We fought hard to get him into Dr. Patrick Soon-Shiong’s clinic. He’s now on #ANKTIVA and PD-L1 NK cell infusions—his latest brain scan is NORMAL!
This treatment needs to be available to ALL cancer patients nationwide—stop slow-walking it, @FDA! Dr. Pat holds the key; let’s unlock it for everyone. Grateful for sharing this story. #Immunotherapy @POTUS
Why haven't we cured cancer? Is it about will or wealth or is there a reality we are familiar with? Tonight we get answers from the administration's top doctors and physicians - join me now on @NewsNation






















